Basic and Clinical Concepts Related to Vitamin D Metabolism and Action

New England Journal of Medicine

Volumn 297, Issue 19, 1977, Pages 1041-1050

  Haussler, Mark R ^a   Mccain, Toni A ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; COLECALCIFEROL; VITAMIN RECEPTOR;

CLINICAL STUDY; DRUG INDUCED DISEASE; DRUG THERAPY; HYPERPHOSPHATEMIA; HYPOPARATHYROIDISM; IDIOPATHIC HYPERCALCIURIA; INTOXICATION; KIDNEY DISEASE; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALABSORPTION; NEWBORN HYPOCALCEMIA; OSTEOMALACIA; OSTEOPOROSIS; PROTEIN BINDING; REVIEW; RICKETS; SURVEY; THERAPY; VITAMIN D DEFICIENCY; VITAMIN METABOLISM;

ANIMAL; ANTICONVULSANTS; BLOOD PROTEINS; CALCIUM; CALCIUM METABOLISM DISORDERS; DIHYDROXYCHOLECALCIFEROLS; HUMAN; HYDROXYCHOLECALCIFEROLS; HYPOCALCEMIA; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; KIDNEY DISEASES; KIDNEY TUBULES; LIVER DISEASES; MALABSORPTION SYNDROMES; OSTEOMALACIA; OSTEOPOROSIS; PARATHYROID DISEASES; PHOSPHORUS METABOLISM DISORDERS; PROTEIN BINDING; RECEPTORS, DRUG; RENAL OSTEODYSTROPHY; RICKETS; SUPPORT, U.S. GOV'T, P.H.S.; VITAMIN D;

EID: 0017671766     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM197711102971906     Document Type: Review

References (100)

1. Haddad JG, Walgate J: 25-hydroxyvitamin D transport in human plasma: isolation and partial characterization of calcifidiol-binding protein. J Biol Chem 251: 4803–4809, 1976
2. Imawari M, Kida K, Goodman DS: The transport of vitamin D and its 25-hydroxy metabolite in human plasma: isolation and partial characterization of vitamin D and 25-hydroxyvitamin D binding protein. J Clin Invest 58: 514–523, 1976
3. Bouillon R, Van Baelen H, Rombauts W, et al: The purification and characterisation of the human-serum binding protein for 25-hydroxycholecalciferol (Transcalciferin): identity with group-specific component. Eur J Biochem 66: 285–291, 1976
4. Haddad JG Jr, Walgate J: Radioimmunoassay of binding protein for vitamin D and its metabolites in human serum: concentrations in normal subjects and patients with disorders of mineral homeostasis. J Clin Invest 58: 1217–1222, 1976
5. Haddad JG, Birge SJ: Widespread, specific binding of 25-hydroxycholecalciferol in rat tissues. J Biol Chem 250: 299–303, 1975
6. Van Baelen H, Bouillon R, De Moor P: binding of 25-hydroxycholecalciferol in tissues. J Biol Chem 252: 2515–2518, 1977
7. Brumbaugh PF, Haussler MR: Nuclear and cytoplasmic binding components for vitamin D metabolites. Life Sci 16: 353–362, 1975
8. Haddad JG Jr, Hahn TJ: Natural and synthetic sources of circulating 25-hydroxyvitamin D in man. Nature 244: 515–517, 1973
9. Belsey R, DeLuca HF, Potts JT Jr: Competitive binding assay for vitamin D and 25-OH vitamin D. J Clin Endocrinol Metab 33: 554–557, 1971
10. Belsey RE, DeLuca HF, Potts JT Jr: A rapid assay for 25-OH-vitamin D3 without preparative chromatography. J Clin Endocrinol Metab 38: 1046–1051, 1974
11. Haddad JG Jr, Min C, Walgate J, et al: Competition by 24,25-dihydroxycholecalciferol in the competitive protein binding radioassay of 25-hydroxycalciferol. J Clin Endocrinol Metab 43: 712–715, 1976
12. Sklan D, Budowski P, Katz M: Determination of 25-hydroxycholecalciferol by combined thin layer gas chromatography. Anal Biochem 56: 606–609, 1973
13. Koshy KT, VanDerSlik AL: High-pressure liquid chromatographic method for the determination of 25-hydroxycholecalciferol in cow plasma. Anal Biochem 74: 282–291, 1976
14. Björkhem I, Holmberg I: A novel specific assay of 25-hydroxyvitamin D3. Clinica Chimica Acta 68: 215–221, 1976
15. Brumbaugh PF, Haussler DH, Bursac KM, et al: Filter assay for 1α,25-dihydroxyvitamin D3: utilization of the hormone's target tissue chromatin receptor. Biochemistry 13: 4091–4097, 1974
16. Eisman JA, Hamstra AJ, Kream BE, et al: A sensitive, precise and convenient method for determination of 1,25-hydroxyvitamin D in human plasma. Arch Biochem Biophys 176: 235–243, 1976
17. Haussler MR, Baylink DJ, Hughes MR, et al: The assay of 1α,25-dihydroxyvitamin D3: physiologic and pathologic modulation of circulating hormone levels. Clin Endocrinol 5: Suppl: 151s–165s, 1976
18. Haussler MR, Hughes MR, Pike JW, et al: Radioligand and receptor assay for 1,25-dihydroxyvitamin D: biochemical, physiologic and clinical applications, Vitamin D: Biochemical, Chemical, and Clinical Aspects Related to Calcium Metabolism. Edited by AW Norman, K Schaefer, JW Coburn, et al. Berlin, Walter de Gruyter, 1977, pp 473–482
19. Hill LF, Mawer EB, Taylor CM: Determination of plasma levels of 1,25-dihydroxy-cholecalciferol in man, Vitamin D and Problems related to Uremic Bone Disease. Edited by AW Norman, K Schaefer, HG Grigoleit, et al. Berlin, Walter de Gruyter, 1975, pp 755–762
20. Stern PH, Phillips TE, Lucas SV, et al: Bone organ culture bioassay for determination of 1,25-(OH)2D, Vitamin D: Biochemical, Chemical, and Clinical Aspects Related to Calcium Metabolism. Edited by AW Norman, K Schaefer, JW Coburn, et al. Berlin, Walter de Gruyter, 1977, pp 531–540
21. O-Riordan JLH, Graham RF, Dolev E: An assay for 24, 25, 26 dihydroxycholecalciferols in sera, Vitamin D: Biochemical, Chemical, and Clinical Aspects Related to Calcium Metabolism. Edited by AW Norman, K Schaefer, JW Coburn, et al. Berlin, Walter de Gruyter, 1977, pp 519–521
22. Mendelsohn M, Min C, Haddad J, et al: Assay of 24,25-dihydroxyvitamin D in serum. Clin Res 24: 582A, 1976
23. Teitelbaum SL, Bone JM, Stein PM, et al: Calcifediol in chronic renal insufficiency: skeletal response. JAMA 235: 164–167, 1976
24. Barton DHR, Hesse RH, Pechet MM, et al: A convenient synthesis of 1α-hydroxy-vitamin D3. J Am Chem Soc 95: 2748–2749, 1973
25. Semmler EJ, Holick MF, Schnoes HK, et al: The synthesis of 1α,25-dihydroxycholecalciferol: a metabolically active form of vitamin D3. Tetrahedron Lett 40: 4147–4150, 1972
26. Kanis JA, Heynen G, Russell RGG, et al: Biological effects of 24, 25-dihydroxycholecalciferol in man, Vitamin D: Biochemical, Chemical, and Clinical Aspects Related to Calcium Metabolism. Edited by AW Norman, K Schaefer, JW Coburn, et al. Berlin, Walter de Gruyter, 1977, pp 793–795
27. Wasserman RH, Henion JD, Haussler MR, et al: Calcinogenic factor in Solanum malacoxylon: evidence that it is 1,25-dihydroxyvitamin D3-glycoside. Science 194: 853–855, 1976
28. Hughes MR, McCain TA, Chang SY, et al: Presence of 1,25-dihydroxyvitamin D3-glycoside in the calcinogenic plant Cestrum diurnum. Nature 268: 347–349, 1977
29. Herrath DV, Schaeffer K, Kraft D, et al: Effect of Solanum malacoxylon on calcium metabolism in experimental uremia and uremic patients, Vitamin D and Problems related to Uremic Bone Disease. Edited by AW Norman, K Schaefer, HG Grigoleit, DV Herrath, et al. Berlin, Walter de Gruyter, 1975, pp 703–708
30. Norman AW, Johnson RL, Osborn TW, et al: The chemistry and conformational and biological analysis of vitamin D3, its metabolites and analogues. Clin Endocrinol 5: Suppl: 121s–143s, 1976
31. Johnson RL, Okamura WH, Norman AW: Studies on the mode of action of calciferol. X. 24-nor-25-hydroxyvitamin D3, an analog of 25-hydroxyvitamin D3 having “anti-vitamin” activity. Biochem Biophys Res Commun 67: 797–802, 1975
32. Pitt MJ, Haussler MR: Vitamin D: biochemistry and clinical applications. Skelet Radiol 1: 191–208, 1977
33. Holmes AM, Enoch BA, Taylor JL, et al: Occult rickets and osteomalacia amongst the Asian immigrant population. Q J Med 42: 125–149, 1973
34. Richards IDG, Sweet EM, Arneil GC: Infantile rickets persists in Glasgow. Lancet 1: 803–805, 1968
35. Albright F, Butler AM, Bloomberg E: Rickets resistant to vitamin D therapy. Am J Dis Child 54: 529–547, 1937
36. Rasmussen H: Parathyroid hormone, calcitonin, and the calciferols, Textbook of Endocrinology. Fifth edition. Edited by RH Williams. Philadelphia, Saunders, 1974, pp 660–773
37. Coburn JW, Koppel MH, Brickman AS, et al: Study of intestinal absorption of calcium in patients with renal failure. Kidney Int 3: 264–272, 1973
38. Brickman AS, Coburn JW, Norman AW: Action of 1,25-dihydroxycholecalciferol, a potent, kidney-produced metabolite of vitamin D3, in uremic man. N Engl J Med 287: 891–895, 1972
39. Mawer EB, Backhouse J, Taylor CM, et al: Failure of formation of 1,25-dihydroxycholecalciferol in chronic renal insufficiency. Lancet 1: 626–628, 1973
40. Kaye M, Sagar S: Effect of dihydrotachysterol on calcium absorption in uremia. Metabolism 21: 815–824, 1972
41. Rutherford WE, Blondin J, Hruska K, et al: Effect of 25-hydroxycholecalciferol on calcium absorption in chronic renal disease. Kidney Int 8: 320–324, 1975
42. Catto GRD, MacLeod M, Pelc B, et al: 1α-hydroxycholecalciferol: a treatment for renal bone disease. Br Med J 1: 12–14, 1975
43. Tougaard L, Sørensen E, Brøchner-Mortensen J, et al: Controlled trial of 1α-hydroxycholecalciferol in chronic renal failure. Lancet 1: 1044–1047, 1976
44. Hirooka M, Wako H, Kaneko C, et al: Curative effects of 1α-hydroxycholecalciferol on calcium metabolism and bone disease in patients with chronic renal failure. J Nutr Sci Vitaminol (Tokyo) 21: 277–285, 1975
45. Naik RB, Gosling P, Price CP, et al: Whole-body in-vivo neutron activation analysis in assessing treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol. Br Med J 2: 79–83, 1976
46. Henderson RG, Russell RGG, Ledingham JGG, et al: Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure. Lancet 1: 379–394, 1974
47. Brickman AS, Sherrard DJ, Jowsey J, et al: 1,25-dihydroxycholecalciferol: effect on skeletal lesions and plasma parathyroid hormone levels in uremic osteodystrophy. Arch Intern Med 134: 883–888, 1974
48. Brickman AS, Coburn JW, Friedman GR, et al: Comparison of effects of 1α-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man. J Clin Invest 57: 1540–1547, 1976
49. Werner E, Malluche HH, Kutschera J, et al: Intestinal calcium absorption and whole-body calcium retention in various stages of renal insufficiency. Calcif Tissue Res 21: Suppl: 210–215, 1976
50. Oettinger CW, Merrill R, Blanton T, et al: Reduced calcium absorption after nephrectomy in uremic patients. N Engl J Med 291: 458–460, 1974
51. Bayard F, Bec P, Ton That H, et al: Plasma 25-hydroxycholecalciferol in chronic renal failure. Eur J Clin Invest 3: 447–450, 1973
52. Eastwood JB, Harris E, Stamp TCB, et al: Vitamin D-deficiency in the osteomalacia of chronic renal failure. Lancet 2: 1209–1211, 1976
53. Bordier PJ, Tun Chot S, Eastwood JB, et al: Lack of histological evidence of vitamin D abnormality in the bones of anephric patients. Clin Sci 44: 33–41, 1973
54. Fraser D, Kooh SW, Kind HP, et al: Pathogenesis of hereditary vitamin D–dependent rickets: an inborn error of vitamin D metabolism involving defective conversion of 25-hydroxyvitamin D to 1α,25-dihydroxyvitamin D. N Engl J Med 289: 817–822, 1973
55. Russell RGG, Smith R, Walton RJ, et al: 1,25-dihydroxycholecalciferol and 1α-hydroxycholecalciferol in hypoparathyroidism. Lancet 2: 14–17, 1974
56. Kooh SW, Fraser D, DeLuca HF, et al: Treatment of hypoparathyroidism and pseudohypoparathyroidism with metabolites of vitamin D: evidence for impaired conversion of 25-hydroxyvitamin D to 1α,25-dihydroxyvitamin D. N Engl J Med 293: 840–844, 1975
57. Drezner MK, Neelon FA, Haussler M, et al: 1,25-dihydroxycholecalciferol deficiency: the probable cause of hypocalcemia and metabolic bone disease in pseudohypoparathyroidism. J Clin Endocrinol Metab 42: 621–628, 1976
58. Kaplan RA, Haussler MR, Deftos LJ, et al: The role of 1α,25-dihydroxy-vitamin D in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria. J Clin Invest 59: 756–760, 1977
59. Rose CA, Harrison AR: The incidence, investigation and treatment of idiopathic hypercalciuria. Br J Urol 46: 261–274, 1944
60. Albright F, Henneman PH, Benedict PH, et al: Idiopathic hypercalciuria. Proc R Society Med 46: 1077–1081, 1953
61. Pak CYC, Ohata M, Lawrence EC, et al: The hypercalciurias: causes, parathyroid functions, and diagnostic criteria. J Clin Invest 54: 387–400, 1974
62. Coe FL, Kavalach AG: Hypercalciuria and hyperuricosuria in patients with calcium nephrolithiasis. N Engl J Med 291: 1344–1350, 1974
63. Shen F, Baylink D, Nielson R, et al: Increased serum 1,25-dihydroxycholecalciferol (1,25-di OHD3) in patients with idiopathic hypercalciuria (IH). Clin Res 23: 423A, 1975
64. Pak CYC, Kaplan R, Bone H, et al: A simple test for the diagnosis of absorptive, resorptive, and renal hypercalciurias. N Engl J Med 292: 497–500, 1975
65. Shen FH, Baylink DJ, Sherrard DJ, et al: Idiopathic hypercalciuria: the “phosphate leak” hypothesis and the effects of oral phosphate supplement. Clin Res 25: 129A, 1977
66. Arnaud C, Glorieux F, Scriver C: Serum parathyroid hormone in X-linked hypophosphatemia. Science 173: 845–847, 1971
67. Glorieux FH, Scriver CR, Reade TM, et al: Use of phosphate and vitamin D to prevent dwarfism and rickets in X-linked hypophosphatemia. N Engl J Med 287: 481–487, 1972
68. Brickman AS, Coburn JW, Kurokawa K, et al: Actions of 1,25-dihydroxycholecalciferol in patients with hypophosphatemic, vitamin-D-resistant rickets. N Engl J Med 289: 495–498, 1973
69. Rasmussen H, Anast C, Parks J, et al: 1α(OH)D3 in treatment of hypophosphatemic rickets. Clin Res 24: 486A, 1976
70. Haddad JG Jr, Chyu KJ, Hahn TJ, et al: Serum concentrations of 25-hydroxyvitamin D in sex-linked hypophosphatemic vitamin D–resistant rickets. J Lab Clin Med 81: 22–27, 1973
71. O'Doherty PJA, DeLuca HF: Intestinal calcium and phosphate transport in genetic hypophosphatemic mice. Biochem Biophys Res Commun 71: 617–621, 1976
72. Short EM, Binder HJ, Rosenberg LE: Familial hypophosphatemic rickets: defective transport of inorganic phosphate by intestinal mucosa. Science 179: 700–702, 1973
73. Brewer ED, Tsai HC, Szeto S, et al: Maleic acid-induced impairment of conversion of 25-hydroxyvitamin D3 (25 OHD3) to 1,25-dihydroxyvitamin D3 (1,25 [OH]2D3) in vivo and in vitro: implications for Fanconi's syndrome. Clin Res 24: 395A, 1976
74. Kooh SW, Fraser D, Toon R, et al: Response of protracted neonatal hypocalcaemia to 1α,25-dihydroxyvitamin D3. Lancet 2: 1105–1107, 1976
75. Rosen JF, Roginsky M, Nathenson G, et al: 25-hydroxyvitamin D: plasma levels in mothers and their premature infants with neonatal hypocalcemia. Am J Dis Child 127: 220–223, 1974
76. Jowsey J, Riggs BL, Kelly PJ, et al: Effect of combined therapy with sodium fluoride, vitamin D and calcium in osteoporosis. Am J Med 53: 43–49, 1972
77. Heany RP: Pathophysiology of osteoporosis: implications for treatment. Tex Med 70: 37–45, 1974
78. Riggs BL, Jowsey J, Kelly PJ, et al: Role of hormonal factors in the pathogenesis of postmenopausal osteoporosis. Israel J Med Sci 12: 616–620, 1976
79. Gallagher JC, Riggs BL, Eisman J, et al: Impaired production of 1,25-dihydroxyvitamin D in postmenopausal osteoporosis. Clin Res 24: 580A, 1976
80. Bordier P, Pechet MM, Hesse R, et al: Response of adult patients with osteomalacia to treatment with crystalline 1α-hydroxy vitamin D3. N Engl J Med 291: 866–871, 1974
81. Arnaud SB, Goldsmith RS, Lambert PW, et al: 25-hydroxyvitamin D3: evidence of an enterohepatic circulation in man. Proc Soc Exp Biol Med 149: 570–572, 1975
82. Long RG, Skinner RK, Wills MR, et al: Serum-25-hydroxy-vitamin-D in untreated parenchymal and cholestatic liver disease. Lancet 2: 650–652, 1976
83. Hahn TJ, Avioli LV: Anticonvulsant osteomalacia. Arch Intern Med 135: 997–1000, 1975
84. Livingston S, Berman W, Pauli LL: Anticonvulsant drugs and vitamin D metabolism. JAMA 224: 1634–1635, 1973
85. Hahn TJ, Hendin BA, Scharp CR, et al: Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med 287: 900–904, 1972
86. Stamp TCB, Round JM, Rowe DJF, et al: Plasma levels and therapeutic effect of 25-hydroxycholecalciferol in epileptic patients taking anticonvulsant drugs. Br Med J 4: 9–12, 1972
87. Jubiz W, Haussler MR, McCain TA, et al: Plasma 1,25-dihydroxyvitamin D levels in patients receiving anticonvulsant drugs. J Clin Endocrinol Metab 44: 617–621, 1977
88. Harrison HC, Harrison HE: Inhibition of vitamin D-stimulated active transport of calcium of rat intestine by diphenylhydantoin-phenobarbital treatment. Proc Soc Exp Biol Med 153: 220–224, 1976
89. Corradino RA: Diphenylhydantoin: direct inhibition of the vitamin D3-mediated calcium absorptive mechanism in organ-cultured duodenum. Biochem Pharmacol 25: 863–864, 1976
90. Jenkins MV, Harris M, Wills MR: The effect of phenytoin on parathyroid extract and 25-hydroxycholecalciferol-induced bone resorption: adenosine 3′, 5′ cyclic monopohsphate production. Calcif Tissue Res 16: 163–167, 1974
91. Brumbaugh PF, Haussler MR: 1α,25-dihydroxyvitamin D3 receptor: competitive binding of vitamin D analogs. Life Sci 13: 1737–1746, 1973
92. Counts SJ, Baylink DJ, Shen FH, et al: Vitamin D intoxication in an anephric child. Ann Intern Med 82: 196–200, 1975
93. Levin ME, Boisseau VC, Avioli LV: Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. N Engl J Med 294: 241–245, 1976
94. Jurist JM: In vivo determination of the elastic response of bone. II. Ulnar resonant frequency in osteoporotic, diabetic and normal subjects. Phys Med Biol 15: 427–434, 1970
95. Schnieder LE, Schedl HP, McCain T, et al: Experimental diabetes reduces circulating 1,25-dihydroxyvitamin D in the rat. Science 196: 1452–1454, 1977
96. Velentzas C, Oreopoulos DG, From G, et al: Vitamin D levels in thyrotoxicosis. Lancet 1: 370–371, 1977
97. Oikawa A, Nakayasu M: Stimulation of melanogenesis in cultured melanoma cells by calciferols. Febs Lett 42: 32–35, 1974
98. Omdahl JL, DeLuca HF: Strontium induced rickets: metabolic basis. Science 174: 949–951, 1971
99. Tsuchiya K: Epidemiological studies on cadmium in the environment in Japan: etiology of itai-itai disease. Fed Proc 35: 2412–2418, 1976
100. Morey E, Haller R, Baylink D: Cessation of bone formation during space flight. Clin Res 25: 161A, 1977